AIRSUPRA (albuterol sulfate and budesonide) by AstraZeneca is corticosteroid hormone receptor agonists [moa]. Approved for asthma. First approved in 2023.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
AIRSUPRA is a metered-dose inhaled aerosol combining albuterol sulfate (short-acting beta-2 agonist) and budesonide (inhaled corticosteroid) for the treatment of asthma. It works through corticosteroid hormone receptor agonism to reduce airway inflammation while providing rapid bronchodilation. This combination therapy addresses both acute symptoms and underlying inflammation in asthma management.
Product is in peak revenue phase with modest Part D adoption; commercial teams are focused on market penetration against established competitors rather than launch intensity.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
GRANITE: Airsupra Effectiveness in the Real World
Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma
Worked on AIRSUPRA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOE in ~4 years — strategic planning for patent cliff underway
AIRSUPRA roles focus on defending and growing market share against entrenched competitors in a high-competition indication; career trajectory depends on ability to differentiate device usability and drive payer adoption. Position offers moderate stability through 2030 LOE but requires strategic execution to maximize peak revenue and prepare for generic entry.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo